New cancer drugs arrive in Libya as healthcare system modernises

Libya’s healthcare system has taken a notable step forward with the arrival of advanced cancer treatments, offering new hope to patients while highlighting a broader push to modernise medical services in a system long under strain.

The National Cancer Control Authority confirmed it has received shipments of Enhertu (100 mg), developed by AstraZeneca, a therapy regarded as one of the most advanced options globally for certain cancers, as reported by Libya Review on April 20^th.

Officials say its introduction could significantly improve treatment outcomes for patients who previously had limited options within the country.

Alongside this, Venclexta (100 mg), produced by AbbVie, has also arrived, further expanding Libya’s ability to treat complex oncology cases. Together, the two drugs mark what authorities described as a “qualitative leap” in cancer care.

The development comes amid wider efforts to overhaul Libya’s medical sector, including ongoing hospital inspections and reform initiatives to improve standards of care.

These measures form part of a broader strategy to reduce reliance on treatment abroad, which has historically placed heavy financial and emotional pressure on patients and their families.

However, progress is unfolding against a challenging backdrop. Reports of systemic weaknesses, including instability and corruption, have underscored the difficulties facing reform efforts.

At the same time, there have been signs of gradual improvement, with local facilities increasingly performing specialised procedures and expanding their capabilities.

International involvement has also played a role, with foreign investment, such as from Italy, supporting developments in key sectors, including healthcare.

This has contributed to a slow but steady strengthening of infrastructure and access to modern treatments.

The National Cancer Control Authority said it will continue working to secure cutting-edge therapies and refine treatment protocols. While challenges remain, the arrival of these drugs signals a meaningful shift towards more advanced and accessible cancer care in Libya.

Libya Review and agencies, Maghrebi.org